Imiquimod is a topical drug that binds to the Toll-like receptor 7, which activates a transcription factor, nuclear factor kappa-B, that causes the release of inflammatory cytokines. This action recruits immune cells to the area of cytokine release.
The drug is indicated for the treatment of patients with actinic keratoses and superficial basal cell carcinoma, among other skin conditions.